Evaluation of clinical signs and histological EAE in WT, B cell–deficient (JHT), B–MHC II+/+, and B–MHC II−/− mice
| Mice and Ag | Incidence | Onset | Mean maximal clinical score | Cumulative score | Mean number of foci (±SEM)a | ||
| Meninges | Parenchyma | Total | |||||
| WT | |||||||
| MOG p35–55 | 5/5 | 11.8 (±0.6) | 3.5 (±0.5) | 295.0 | 126 (±69) | 137 (±69) | 263 (±138) |
| rmMOG | 5/5 | 12.0 (±0.6) | 4.0 (±0.3) | 336.5 | 122 (±42) | 149 (±45) | 271 (±87) |
| rhMOG | 5/5 | 12.8 (±0.5) | 3.5 (±0.4) | 291.0 | 154 (±47) | 150 (±10) | 304 (±57) |
| JHT | |||||||
| MOG p35–55 | 5/5 | 11.8 (±0.7) | 3.5 (±0.3) | 288.0 | 98 (±25) | 128 (±55) | 226 (±80) |
| rmMOG | 5/5 | 11.2 (±0.4) | 3.9 (±0.5) | 325.0 | 103 (±18) | 125 (±24) | 228 (±42) |
| rhMOG | 0/5 | - | 0.0 (±0.0) | 0.0 | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 (±0.0) |
| B–MHC II+/+ | |||||||
| MOG p35–55 | 5/5 | 8.8 (±1.3) | 3.2 (±0.3) | 113.5 | 178 (±13) | 147 (±8) | 325 (±21) |
| rmMOG | 5/5 | 8.4 (±0.5) | 3.4 (±0.2) | 124.0 | 151 (±43) | 131 (±19) | 282 (±62) |
| rhMOG | 5/5 | 8.2 (±0.8) | 3.7 (±0.2) | 136.5 | 109 (±17) | 148 (±27) | 257 (±34) |
| B–MHC II−/− | |||||||
| MOG p35–55 | 5/5 | 10.2 (±0.8) | 2.9 (±0.2) | 95.0 | 142 (±22) | 177 (±43) | 319 (±65) |
| rmMOG | 5/5 | 8.8 (±0.4) | 2.8 (±0.1) | 95.5 | 107 (±33) | 87 (±7) | 194 (±40) |
| rhMOG | 0/5 | - | 0.0 (±0.0) | 0.0 | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 (±0.0) |
| Mice and Ag | Incidence | Onset | Mean maximal clinical score | Cumulative score | Mean number of foci (±SEM)a | ||
| Meninges | Parenchyma | Total | |||||
| WT | |||||||
| MOG p35–55 | 5/5 | 11.8 (±0.6) | 3.5 (±0.5) | 295.0 | 126 (±69) | 137 (±69) | 263 (±138) |
| rmMOG | 5/5 | 12.0 (±0.6) | 4.0 (±0.3) | 336.5 | 122 (±42) | 149 (±45) | 271 (±87) |
| rhMOG | 5/5 | 12.8 (±0.5) | 3.5 (±0.4) | 291.0 | 154 (±47) | 150 (±10) | 304 (±57) |
| JHT | |||||||
| MOG p35–55 | 5/5 | 11.8 (±0.7) | 3.5 (±0.3) | 288.0 | 98 (±25) | 128 (±55) | 226 (±80) |
| rmMOG | 5/5 | 11.2 (±0.4) | 3.9 (±0.5) | 325.0 | 103 (±18) | 125 (±24) | 228 (±42) |
| rhMOG | 0/5 | - | 0.0 (±0.0) | 0.0 | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 (±0.0) |
| B–MHC II+/+ | |||||||
| MOG p35–55 | 5/5 | 8.8 (±1.3) | 3.2 (±0.3) | 113.5 | 178 (±13) | 147 (±8) | 325 (±21) |
| rmMOG | 5/5 | 8.4 (±0.5) | 3.4 (±0.2) | 124.0 | 151 (±43) | 131 (±19) | 282 (±62) |
| rhMOG | 5/5 | 8.2 (±0.8) | 3.7 (±0.2) | 136.5 | 109 (±17) | 148 (±27) | 257 (±34) |
| B–MHC II−/− | |||||||
| MOG p35–55 | 5/5 | 10.2 (±0.8) | 2.9 (±0.2) | 95.0 | 142 (±22) | 177 (±43) | 319 (±65) |
| rmMOG | 5/5 | 8.8 (±0.4) | 2.8 (±0.1) | 95.5 | 107 (±33) | 87 (±7) | 194 (±40) |
| rhMOG | 0/5 | - | 0.0 (±0.0) | 0.0 | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 (±0.0) |
Onset indicates mean day of disease onset (paralytic EAE) ± SEM. Clinical score shows mean maximal score of paralytic EAE of diseased mice ± SEM. Cumulative score shows sum of the daily scores of all animals from day 0 until the end of the experiment. Results are representative of five separate experiments (five mice/group/experiment).
The infiltration in the brain and spinal cord is quantified as averaged number of meningeal and parenchymal inflammatory foci (>10 clustered inflammatory cells) per CNS tissue section (five mice/group).